Telesis Bio Statistics
Total Valuation
Telesis Bio has a market cap or net worth of $9.67 million. The enterprise value is $24.72 million.
| Market Cap | 9.67M |
| Enterprise Value | 24.72M |
Important Dates
The next estimated earnings date is Thursday, May 9, 2024, after market close.
| Earnings Date | May 9, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Telesis Bio has 30.10 million shares outstanding. The number of shares has increased by 1.31% in one year.
| Shares Outstanding | 30.10M |
| Shares Change (YoY) | +1.31% |
| Shares Change (QoQ) | +0.22% |
| Owned by Insiders (%) | 37.68% |
| Owned by Institutions (%) | 37.05% |
| Float | 9.10M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.35 |
| Forward PS | 0.27 |
| PB Ratio | 40.64 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 0.90 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.71, with a Debt / Equity ratio of 144.45.
| Current Ratio | 3.71 |
| Quick Ratio | 3.09 |
| Debt / Equity | 144.45 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -14.36 |
Financial Efficiency
Return on equity (ROE) is -237.60% and return on invested capital (ROIC) is -134.44%.
| Return on Equity (ROE) | -237.60% |
| Return on Assets (ROA) | -51.70% |
| Return on Capital (ROIC) | -134.44% |
| Revenue Per Employee | $200,796 |
| Profits Per Employee | -$357,839 |
| Employee Count | 137 |
| Asset Turnover | 0.29 |
| Inventory Turnover | 3.39 |
Taxes
In the past 12 months, Telesis Bio has paid $24,000 in taxes.
| Income Tax | 24,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -87.55% in the last 52 weeks. The beta is 1.92, so Telesis Bio's price volatility has been higher than the market average.
| Beta (1Y) | 1.92 |
| 52-Week Price Change | -87.55% |
| 50-Day Moving Average | 0.45 |
| 200-Day Moving Average | 0.74 |
| Relative Strength Index (RSI) | 32.75 |
| Average Volume (30 Days) | 767,811 |
Short Selling Information
The latest short interest is 100,415, so 0.33% of the outstanding shares have been sold short.
| Short Interest | 100,415 |
| Short Previous Month | 226,264 |
| Short % of Shares Out | 0.33% |
| Short % of Float | 1.10% |
| Short Ratio (days to cover) | 0.63 |
Income Statement
In the last 12 months, Telesis Bio had revenue of $27.51 million and -$49.02 million in losses. Loss per share was -$1.64.
| Revenue | 27.51M |
| Gross Profit | 16.95M |
| Operating Income | -46.54M |
| Pretax Income | -47.70M |
| Net Income | -49.02M |
| EBITDA | -40.49M |
| EBIT | -44.60M |
| Loss Per Share | -$1.64 |
Balance Sheet
The company has $19.33 million in cash and $34.38 million in debt, giving a net cash position of -$15.05 million or -$0.50 per share.
| Cash & Cash Equivalents | 19.33M |
| Total Debt | 34.38M |
| Net Cash | -15.05M |
| Net Cash Per Share | -$0.50 |
| Equity / Book Value | 238,000 |
| Book Value Per Share | 0.01 |
| Working Capital | 22.17M |
Cash Flow
In the last 12 months, operating cash flow was -$34.67 million and capital expenditures -$1.96 million, giving a free cash flow of -$36.63 million.
| Operating Cash Flow | -34.67M |
| Capital Expenditures | -1.96M |
| Free Cash Flow | -36.63M |
| FCF Per Share | -$1.23 |
Margins
Gross margin is 61.62%, with operating and profit margins of -169.18% and -178.21%.
| Gross Margin | 61.62% |
| Operating Margin | -169.18% |
| Pretax Margin | -173.40% |
| Profit Margin | -178.21% |
| EBITDA Margin | -147.20% |
| EBIT Margin | -162.11% |
| FCF Margin | -133.16% |
Dividends & Yields
Telesis Bio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.31% |
| Shareholder Yield | -1.31% |
| Earnings Yield | -506.86% |
| FCF Yield | -378.72% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | Hold |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Telesis Bio has an Altman Z-Score of -4.39 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -4.39 |
| Piotroski F-Score | 2 |